Levodopa (L-DOPA) remains the most effective pharmacological treatment for Parkinson Disease (PD) but its use is limited by the development of debilitating drug-related side effects, particularly L-DOPA induced dyskinesia (LID). LID is a consequence of long-term L-DOPA use, and in model systems is characterized by a "priming effect", whereby initial administrations of L-DOPA trigger a sensitized biochemical and transcriptional response upon subsequent dopaminergic stimulation. Preliminary studies into the mechanisms underlying this cellular memory have indicated an important role for epigenetic change but many of the downstream mechanisms remain unknown. The family of bromodomain and extraterminal (BET) proteins, which bind acetylated histones, play a critical effector role in the regulation of transcription. BET proteins have been implicated in several forms of neural plasticity, but their potential relevance to LID remains unexplored. Using the 6-OHDA rodent model of LID, we show that dyskinesia development induces alterations in BET protein expression along with enhanced occupation of sites at the promoter and enhancer regions of genes dysregulated during dyskinesia development. When BET function was blocked using the pharmacologic inhibitor JQ1, LID was prevented. In addition, we found that JQ1 treatment blocked the transcriptional upregulation of several immediate-early genes known to participate in the pathogenesis of dyskinesia. Together, these results demonstrate an essential role for BET protein activity as an epigenetic "reader" of the altered histone acetylation required for LID development and suggest that modulation of BET protein function is a potential therapeutic avenue for the prevention or reversal of LID in PD.
Introduction
While levodopa (L-DOPA) is currently the best available treatment for Parkinson disease (PD), its therapeutic potential is limited due to a progressive narrowing of the therapeutic window and the development of motor complications from L-DOPA therapy. Levodopa-induced dyskinesia (LID) is often the most troubling of these complications, producing involuntary, choreiform movements that can be extremely disabling (Grandas et al., 1999; Fahn, 2000) . Dyskinetic behaviors develop following repeated L-DOPA treatment and are usually seen during the peak of plasma L-DOPA concentrations. In clinical populations the prevalence of LID in L-DOPA-treated PD patients is nearly 50% at 5 years, and is estimated as high as 90% at 10 years (Rascol et al., 2000; Poewe, 2009 ). Once dyskinesias have been established they are usually persistent and recur with every L-DOPA dose, suggesting the pathophysiological release of unintended motor programs stored in the basal ganglia (Pisani et al., 2005; Belujon et al., 2010) .
Biochemical and physiologic investigations have indicated that dysregulation of corticostriatal plasticity is an important mechanism underlying LID development. In animal models, there is a loss of bidirectional synaptic plasticity and sensitization in striatal MAPK/Erk signaling that causes downstream changes to CREB and AP-1 dependent transcription (Picconi et al., 2003; Santini et al., 2009; Heiman et al., 2014; Charbonnier-Beaupel et al., 2015) . Examples of these alterations in cellular behavior have been found in rodent and non-human primate models following LID development, and are known to be very long-lasting, quickly reemerging following periods of prolonged treatment interruption (Bezard et al., 2001; Fahn et al., 2004; Brotchie, 2005) . Although sensitization of striatal signaling is able to explain the expression of dyskinetic behaviors following L-DOPA administration, the mechanisms behind the long-term maintenance of these changes in cellular responsiveness remain unknown.
Following LID development, dysregulated transcription factor activity leads to the sustained over expression of several activity regulated immediate-early genes (IEG) essential to the formation of long-term neuronal memory (Nestler et al., 2001; West et al., 2002; Figge et al., 2013) . Studies in LID animal models have indicated that the aberrant gene expression is due to sustained alterations in epigenetic modifications that control chromatin accessibility. Recent work has indicated an essential role for dynamic striatal DNA methylation in the 
